ArticleCell communication and signaling : CCS2026
Atox1 promotes CRC progression by protecting DNA damage through interacts with a novel copper-binding protein PARP1.
Article in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
The copper chaperone antioxidant 1 (Atox1) is a key driver in several cancers, with increased expression associated with poor survival. Its role in colorectal cancer (CRC) had been largely unexplored. Based on TCGA data and clinical samples, we found elevated Atox1 expression in CRC. Knockdown of Atox1 suppressed cell proliferation and tumor growth in vitro and in vivo, and silencing it led to DNA damage in CRC cells. Further experiments showed that Atox1 directly interacted with Poly(ADP-ribose) polymerase 1 (PARP1) at the copper binding site and positively regulated its activity. Mechanistic studies indicated that PARP1 is a novel copper-binding protein, and excessive copper inhibited PARP1’s enzymatic activity and weakened DNA damage repair. Atox1 relieves copper’s inhibitory effect on PARP1. Targeting Atox1 with DC_AC50 also induced DNA damage, suppressed cell proliferation, and inhibited tumor growth in CRC. The combination of DC_AC50 and Olaparib had a stronger inhibitory effect on CRC growth. This research demonstrated that Atox1 interacts with PARP1, a novel copper-binding protein, by regulating DNA damage, cell proliferation, and tumor growth in CRC. The Atox1 - PARP1 axis could be a prospective therapeutic target for CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.